JENNIFER ARMSTRONG: Open Payments
NPI 1952133506 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,721 in 184 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $2,866 · 2025 $4,721
Food & beverage: $4,721
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $803 |
| E.R. Squibb & Sons, L.L.C. | 15 | $621 |
| Alkermes, Inc. | 18 | $528 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $521 |
| Supernus Pharmaceuticals, Inc. | 25 | $514 |
| Tris Pharma Inc | 10 | $300 |
| Teva Pharmaceuticals USA, Inc. | 22 | $235 |
| Vanda Pharmaceuticals Inc. | 15 | $207 |
| Neurocrine BioSciences, Inc. | 7 | $205 |
| Luye Pharma (USA) Ltd. | 5 | $202 |
Products named: VRAYLAR, COBENFY, CAPLYTA, Qelbree, ARISTADA, FANAPT, INGREZZA, ERZOFRI EXTENDED-RELEASE.
Industry payments across MO — which companies pay providers there.
